Outcome	No. of studies	No. of participants	Statistical method	Effect size	Vaccine efficacy (95% CI)
Confirmed SARS‐CoV‐2 infection after complete vaccination	1	25,435	N/A	N/A	73.50% (60.60% to 82.20%)
Confirmed symptomatic COVID‐19 after complete vaccination	1	25,463	N/A	N/A	78.10% (64.80% to 86.30%)
Severe or critical COVID‐19 after complete vaccination	N/A	N/A	N/A	N/A	N/A
All‐cause mortality	N/A	N/A	N/A	N/A	N/A
Serious adverse events	1	26,924	Risk Ratio (M‐H, Random, 95% CI)	0.76 (0.54 to 1.06)	N/A
Systemic reactogenicity events	3	27,540	Risk Ratio (M‐H, Random, 95% CI)	1.05 (0.86 to 1.28)	N/A
Any adverse event	3	27,540	–	Not pooled due to high heterogeneity	N/A
Local reactogenicity events	3	27,540	–	Not pooled due to high heterogeneity	N/A